Physician profile
Phi H Le
NPI 1568475200
$7,560.80
in general payments reported to CMS, 2019-2025
27 companies · $940 in 2025
The $940 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,230 · 2020: $1,186 · 2021: $985 · 2022: $501 · 2023: $732 · 2024: $987 · 2025: $940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,659.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,680.50 | 2019-2023 | Xarelto |
| Amgen INC. | $1,600.63 | 2019-2025 | Repatha, Otezla, Repatha |
| Heartflow, INC. | $618.08 | 2023-2025 | Ffrct |
| Novo Nordisk INC | $441.73 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbott Laboratories | $374.89 | 2023-2025 | Freestyle Libre 3, Freestyle Libre, Freestyle Libre 2 |
| Esperion Therapeutics, INC. | $340.41 | 2020-2024 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $293.88 | 2022-2024 | |
| Amarin Pharma, INC. | $237.32 | 2019-2021 | |
| Lilly USA, LLC | $149.40 | 2020-2024 | Mounjaro, Zepbound |
| Pfizer INC. | $145.71 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $141.83 | 2019-2020 | |
| Edwards Lifesciences Corporation | $98.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $59.88 | 2021-2025 | |
| Biosense Webster, INC. | $59.33 | 2023 | Carto 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.50 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $46.02 | 2022-2023 | Shingrix, Arexvy |
| Sun Pharmaceutical Industries INC. | $42.82 | 2022-2023 | Absorica Ld, Winlevi |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $29.25 | 2019 | |
| Phathom Pharmaceuticals, INC. | $25.00 | 2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $23.24 | 2019 | |
| Astellas Pharma US INC | $19.19 | 2024 | Veozah |
| Sebela Pharmaceuticals INC. | $18.06 | 2022 | |
| Leo Pharma INC. | $15.83 | 2023 | Adbry |
| Epi Health, LLC | $14.89 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $14.83 | 2022 | |
| Allergan, INC. | $13.87 | 2020 | |
| Biofrontera INC. | $2.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phi Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.